STUDY SHOWS PINE BARK NATURALLY REDUCES OSTEOARTHRITIS Wednesday 16 April 2008 PDF Print A new study has shown that Pycnogenol® , a natural pine bark extract, has the ability to naturally reduce pain and increase mobility in those suffering from osteoarthritis. The study revealed a particularly high efficacy of Pycnogenol® for lowering joint pain by 55 percent, joint stiffness by 53 percent and increasing patients mobility almost three-fold. Overall osteoarthritis symptoms were shown to be reduced by 56 percent and moreover, patients required dramatically less standard pain medication. “Pycnogenol® seemed a natural fit for this study,” said Dr. Gianni Belcaro, a lead researcher of the study. “There are a few main components contributing to the clinical picture of treatment management in osteoarthritis: • inflammation causing a progression in the disease • alteration of fatigue resistance • muscular performance—reversing and blocking the vascular problems associated to altered mobility. Theoretically, a treatment with a compound specifically active on all those aspects could be highly effective, which is why we chose Pycnogenol®.” After three months, scores for pain dropped significantly for the Pycnogenol® treatment group and no significant effects were recorded for the placebo group. Scores for stiffness were reduced by 53 percent. The scores for physical function were reduced by 57 percent in the Pycnogenol® group and improvement under placebo was not significant. The global WOMAC score decreased following Pycnogenol® treatment and very little in the placebo group, from 56 percent vs. 9.6 percent for Pycnogenol® and placebo, respectively. Pycnogenol® is a natural plant extract originating from the bark of the maritime pine that grows along the coast of southwest France and is found to contain a unique combination of procyanidins, bioflavonoids and organic acids, which offer extensive natural health benefits. The extract has been widely studied for the past 35 years and has more than 220 published studies and review articles ensuring safety and efficacy as an ingredient. Today, Pycnogenol® is available in more than 600 dietary supplements, multi-vitamins and health products worldwide. “The results of this study are significant as they clearly demonstrate the clinical action of Pycnogenol® on OA and management of symptoms. The use of Pycnogenol® may reduce costs and side effects of anti-inflammatory agents and offer a natural alternative solution to people suffering from OA” said Dr. Belcaro. The benefits of Pycnogenol® for arthritic joints are suggested to result predominantly from the anti-inflammatory potency of Pycnogenol® which was demonstrated in a series of clinical investigations in the past. There are more breakthrough studies on Pycnogenol® and osteoarthritis expected to be published next year allowing for development of innovative, natural formulas for joint health. The randomized, double-blind, placebo-controlled study, held at Italy’s Chieti-Pescara University, sampled 156 patients with osteoarthritis of the knee (OA). Patients were administered 100 mg Pycnogenol® or placebo, daily for three months. Symptoms were evaluated by WOMAC index scores and mobility by recording their walking performance on a treadmill. Patients were permitted to continue taking their choice of pain medication provided they recorded every tablet in a diary for later evaluation. ENDS This new study is to be published in the April 2008 edition (Volume 22, issue No 4) of the journal of Phytotherapy Research. About Pycnogenol ® Pycnogenol® is available from independent health food stores, and pharmacies, priced from £14.75 for 30 capsules. For more information go to www.pycnogenol.com, for specific brand details please contact press office below: Issued by: Pegasus Public Relations On behalf of: Horphag Research Press enquiries: Sallyanne Jones/Rebecca Gobel (01903) 821550 Email: firstname.lastname@example.org Ref: 8249 16th April 2008 Notes to Editors: Research Methodology To describe and rate osteoarthritis symptoms (joint pain, stiffness and physical function), WOMAC questionnaires were evaluated by the investigator and patient at the start and after three months of treatment. Patients were trained on a treadmill test and performance evaluation was recorded on total distance that could be covered without pain. Measuring foot volume by the water-displacement method was used to evaluate ankle/foot edema in a randomly selected subgroup of subjects within the two treatment groups. After three months, scores for pain dropped significantly for the Pycnogenol® treatment group and no significant effects were recorded for the placebo group. Scores for stiffness were reduced by 53 percent. The scores for physical function were reduced by 57 percent in the Pycnogenol® group and improvement under placebo was not significant. The global WOMAC score decreased following Pycnogenol® treatment and very little in the placebo group, from 56 percent vs. 9.6 percent for Pycnogenol® and placebo, respectively. Overall well-being of patients (emotional function) was significantly enhanced with the Pycnogenol® group, by 64 percent and 15 percent for the placebo group. Results of exercise tests on the treadmill demonstrated an increased performance after three months of Pycnogenol® treatment. At the start of the study, patients could only walk a mean of 74 yards without feeling pain and after three months, they could walk 216 yards, compared to the placebo group that noted 71 yards at the beginning of the study and 96 yards at the end. In addition to the osteoarthritis results, 76 percent of the patients in the Pycnogenol® group and 79 percent in the placebo group showed visible ankle and foot edema at inclusion of the study. After the three months, edema decreased in 79 percent of the Pycnogenol® patients and only one percent in placebo-treated patients. Patients were allowed to use their regular dosage of NSAIDS. Usage dropped by 58 percent during treatment with Pycnogenol® and one percent with the placebo. Evaluation of data demonstrated a decrease of gastrointestinal complications of 64 percent in the Pycnogenol® group versus three percent in placebo. This press release was distributed by ResponseSource Press Release Wire on behalf of Pegasus Public Relations (Worthing) in the following categories: Men's Interest, Health, Women's Interest & Beauty, Sport, Medical & Pharmaceutical, for more information visit http://pressreleasewire.responsesource.com/about.